Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 5Breast 4Other hematologic neoplasm 3Lymphoid 3Plasma cell 2Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Dermatologic 1CNS 1

Conditions

Multiple Myeloma 2Neoplasms 1Nausea 1Lymphoma 1

Interventions

Dexamethasone 393Bortezomib 246Lenalidomide 222Cyclophosphamide 184Melphalan 168Calcium Dobesilate 119Peripheral Blood Stem Cell Transplantation 94fludarabine phosphate 89Thalidomide 82Filgrastim 74carfilzomib 70pomalidomide 68Granulocyte Colony-Stimulating Factor 63Busulfan 63Mycophenolic Acid 61daratumumab 58Whole-Body Irradiation 57ixazomib 54fludarabine 52Tacrolimus 52Prednisone 51Cyclosporine 50Antilymphocyte Serum 35dexamethasone acetate 32plerixafor 30Etoposide 30Methotrexate 29Radiotherapy 28dexamethasone 21-phosphate 27Doxorubicin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Palonosetron × Plasma cell × Clear all
NCT00600353 2017-03-09

Multi-day Doses in Prevention of Nausea and Emesis

University of Kansas Medical Center

Phase 2 Completed
20 enrolled 8 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Nausea, Neoplasms

NCT00306735 2016-12-05

Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.

Eisai Inc.

Phase 2 Completed
75 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡